The value of supporting care in IC: Managing myelosuppression
This site is intended for United Kingdom/Ireland healthcare professionals
Safety Profile Comparable to DA Therapy in Patients With AML-MRC and t-AML1
Comparable Overall Frequency and Severity of Grade 3–5 AEs vs DA Therapy2-5
Refer to section 4.8 of the Summary of Product Characteristics for full safety information3
Five patients experienced AEs that led to treatment discontinuation:2
- Vyxeos Liposomal: Cardiac failure, cardiomyopathy, and acute renal failure in one patient each
- Conventional chemotherapy: Decreased ejection fraction in two patients
Prolonged Myelosuppression vs DA Therapy3
Vyxeos Liposomal is associated with prolonged thrombocytopenia and neutropenia vs DA therapy, so patients will require additional monitoring3
Explore the safety data from the real-world evidence studies in detail here
RELATED CONTENT
Vyxeos Liposomal delivers quadruple endpoint superiority vs DA 3+72
mOS – p=0.003 • Post-HSCT mOS – p=0.009 CR/CRi – p=0.016 • EFS – p=0.021